Drug search by name

Exenatide Extended-Release Injection (Bydureon BCise) and Pancreatitis

Result of checking the interaction of drug Exenatide Extended-Release Injection (Bydureon BCise) and disease Pancreatitis for safety when used together.

Check result:

Exenatide Extended-Release Injection (Bydureon BCise) <> Pancreatitis

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis. Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk. Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis. If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated. Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.

Exenatide Extended-Release Injection (Bydureon BCise)

Generic Name: exenatide

Brand Name: Byetta Prefilled Pen, Bydureon, Bydureon BCise, Bydureon Pen, Bydureon Tray

Synonyms: Exenatide

What is Exenatide Extended-Release Injection (Bydureon BCise)?